Clinical trials have investigated various combination therapies to improve the effectiveness of BRAF inhibitors in the treatment of metastatic melanoma, such as the combination of MEK inhibitors and immune checkpoint blockade [52–54]. This evidence concerns the gene MAP2K7 and metastatic melanoma.